Journal of Bioethical Inquiry 2 (2) (2005)
|Abstract||Drug promotion should be evaluated according to its impact on health, access to information, informed consent, and wealth. Drug promotion currently does more harm than good to each of these objectives because it is usually misleading. This is a systemic problem. Whilst improved regulation and education will address it to some degree, major reforms to payment systems for drug companies and doctors are also required. Until all these systemic reforms can be put in place, the best policy option is to ban the promotion of drugs to doctors and the public. Consequently, pending major reforms, it is appropriate for governments to restrict drug promotion as much as is politically achievable.|
|Keywords||No keywords specified (fix it)|
|Through your library||Configure|
Similar books and articles
Rinaldo B. Schinazi (2006). The Probability of Treatment Induced Drug Resistance. Acta Biotheoretica 54 (1).
Hugh LaFollette (1994). Mandatory Drug Testing. In Steven Luper & C. Brown (eds.), Drugs, Morality, and the Law. Garland.
Peter Allmark (2005). Health, Happiness and Health Promotion. Journal of Applied Philosophy 22 (1):1–15.
Michael Huemer (2004). America's Unjust Drug War. In Bill Masters (ed.), The New Prohibition. Accurate Press.
Hugh LaFollette (1994). Mandatory Drug Testing. In S. Luper & C. Brown (eds.), Drugs, Morality, and the Law. Garland.
John Sabini & John Monterosso (2005). Judgments of the Fairness of Using Performance Enhancing Drugs. Ethics and Behavior 15 (1):81 – 94.
Stephen R. Latham (2010). Speaking Off Label. Hastings Center Report 40 (6).
Added to index2009-01-28
Total downloads10 ( #106,175 of 548,984 )
Recent downloads (6 months)1 ( #63,327 of 548,984 )
How can I increase my downloads?